Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.
Who will be affected?
Readers: No access to all 28 journals. We recommend accessing our articles via PubMed Central
Authors: No access to the submission form or your user account.
Reviewers: No access to your user account. Please download manuscripts you are reviewing for offline reading before Wednesday, July 01, 2020 at 7:00 PM.
Editors: No access to your user account to assign reviewers or make decisions.
Copyeditors: No access to user account. Please download manuscripts you are copyediting before Wednesday, July 01, 2020 at 7:00 PM.
Prescribing Patterns of Dupilumab for Atopic Dermatitis in Adults: A Retrospective, Observational Cohort Study
Torunn Sivesind;
Ani Oganesyan;
Grace Bosma;
Camille Hochheimer;
Lisa Schilling;
Robert Dellavalle
ABSTRACT
Background:
Atopic dermatitis (AD) is a common inflammatory disease caused by type 2 helper T-cell (Th2) mediated immune response to environmental antigens. Dupilumab, a fully human monoclonal antibody, improves AD via inhibition of interleukin (IL)-4 and IL-13.
Objective:
Our aim was to characterize prescribing patterns of dupilumab for AD in adults at a large health system.
Methods:
A retrospective, observational cohort study was conducted using electronic data from the University of Colorado Medical Campus and its affiliates. The outcome measured was the prevalence of dupilumab prescribed for adults with AD, between 3/28/2013-3/28/2021. We assessed whether the characteristics of patients who received dupilumab were different from those who did not.
Results:
We found a population AD prevalence of 5.6%. In our cohort, Black patients were more than twice as likely to have received dupilumab than were White patients. Patients with a diagnosis of atopic neurodermatitis were approximately twice as likely to have received dupilumab than those with other diagnostic variants of AD.
Conclusions:
Our results demonstrate that both patient racial characteristics and specific AD diagnoses were associated with variations in dupilumab prescription patterns. Clinical Trial: NA
Citation
Please cite as:
Sivesind T, Oganesyan A, Bosma G, Hochheimer C, Schilling L, Dellavalle R
Prescribing Patterns of Dupilumab for Atopic Dermatitis in Adults: Retrospective, Observational Cohort Study